Hooks Corwin Dale 4

What Happened

• Hooks Corwin Dale, Chief Commercial Officer of Spruce Biosciences (SPRB), received a grant of 11,000 restricted stock units (RSUs) on March 9, 2026.
• The filing reports an acquisition price of $0.00 (typical for RSU awards); the award is a derivative right to receive common shares if and when the RSUs vest.

Key Details

• Transaction date and filing date: 2026-03-09 (filed the same day).
• Transaction type: A = Award/Grant (derivative RSUs).
• Shares/units granted: 11,000 RSUs; reported acquisition value $0.00.
• Vesting: 25% of the RSUs vest on March 15, 2027, then 25% on each of March 15, 2028, 2029 and 2030, subject to continuous service.
• Shares owned after transaction: Not specified in the provided filing.
• No 10b5-1 plan, tax-withholding, or late-filing notes were reported in the provided information.

Context

• RSUs are compensation awards that convert to shares upon vesting; they are not an immediate cash purchase or sale and do not by themselves indicate insider buying/selling sentiment.
• Vesting is time-based (four-year schedule) and conditional on continued service; until vesting the RSUs remain a contingent claim on shares.